GeoVax Labs announces CEO David Dodd will present at NobleCon20 on corporate updates and clinical trials.
Quiver AI Summary
GeoVax Labs, Inc., a biotechnology company focused on human vaccines and cancer immunotherapies, announced that its Chairman and CEO, David Dodd, will present at the NobleCon20 conference from December 2-5, 2024, in Boca Raton, FL. Dodd's presentation titled "GeoVax Corporate Update" is scheduled for December 3 at 11:30 am ET, and a high-definition video webcast will be available on the company's website the following day, as well as on Noble Capital Markets' conference platform and Channelchek for 90 days. GeoVax is currently advancing several clinical programs, notably its next-generation COVID-19 vaccine GEO-CM04S1, which has received a BARDA-funded contract for a Phase 2b trial, and the oncolytic therapy Gedeptin®, which is being tested for head and neck cancers. The company emphasizes its strong intellectual property portfolio and experienced leadership team. For further updates, visit their website.
Potential Positives
- David Dodd, Chairman & CEO, will present at a prominent investment conference, enhancing visibility and interest in the company.
- The company's participation in the conference allows for engagement with potential investors through one-on-one meetings, which could lead to increased financial backing.
- GeoVax is progressing with its lead clinical program for a next-generation COVID-19 vaccine, including a major BARDA-funded Phase 2b clinical trial, which signifies strong governmental and institutional support.
- The announcement highlights GeoVax's innovative pipeline, showcasing its commitment to addressing significant health challenges, particularly in infectious diseases and cancer therapies.
Potential Negatives
- The announcement may imply that the company's future funding or development relies heavily on the success of its lead clinical program, creating uncertainty for investors.
- The company's presentation at the conference may highlight unresolved issues or concerns regarding the efficacy or safety of their vaccines and therapies, especially in light of recent scrutiny in the biotech sector.
- The need for one-on-one management meetings suggests that they might be facing challenges in effectively communicating their value proposition to investors, which could raise concerns about investor confidence.
FAQ
What is the date and time of David Dodd's presentation at NobleCon20?
David Dodd will present on December 3, 2024, at 11:30 am ET.
Where will the NobleCon20 conference take place?
The conference will be held at Florida Atlantic University in Boca Raton, FL.
How can I watch David Dodd's presentation?
A high-definition video webcast will be available on GeoVax's website the day after the presentation.
What is GeoVax's primary clinical program?
GeoVax's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
What kind of therapies does GeoVax develop?
GeoVax develops human vaccines for infectious diseases and cancer immunotherapies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$GOVX Insider Trading Activity
$GOVX insiders have traded $GOVX stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $GOVX stock by insiders over the last 6 months:
- DAVID A DODD (President, CEO) purchased 8,000 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$GOVX Hedge Fund Activity
We have seen 8 institutional investors add shares of $GOVX stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RENAISSANCE TECHNOLOGIES LLC added 266,000 shares (+inf%) to their portfolio in Q3 2024
- ARMISTICE CAPITAL, LLC removed 80,000 shares (-100.0%) from their portfolio in Q3 2024
- BANK OF AMERICA CORP /DE/ removed 44,729 shares (-99.9%) from their portfolio in Q3 2024
- GEODE CAPITAL MANAGEMENT, LLC added 42,834 shares (+308.9%) to their portfolio in Q3 2024
- VIRTU FINANCIAL LLC added 40,210 shares (+inf%) to their portfolio in Q3 2024
- TWO SIGMA INVESTMENTS, LP added 22,588 shares (+inf%) to their portfolio in Q3 2024
- CITIGROUP INC added 11,608 shares (+inf%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present at NobleCon20 - the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference taking place December 2-5, 2024 in Boca Raton, FL.
| Presentation Details: | |||
| Speaker: | David Dodd, Chairman & CEO | ||
| Date/Time: | December 3, 2024, 11:30 am ET | ||
| Location: | Florida Atlantic University Executive Education Complex, Boca Raton, FL | ||
| Title: | GeoVax Corporate Update | ||
A high-definition video webcast of the presentation will be available the following day on the Company's website www.geovax.com , and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website: www.nobleconference.com and on Channelchek: www.channelchek.com the investor portal created by Noble. The webcast will be archived on the company's website, the NobleCon website, and on Channelchek.com for 90 days following the event. Senior GeoVax management will also host one-on-one meetings with registered attendees.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial in first recurrent head and neck cancer, evaluating Gedeptin® combined with an immune checkpoint inhibitor is planned to initiate during the first half of 2025. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com .
| Company Contact: | Investor Relations Contact: | Media Contact: | ||
| info@geovax.com | austin.murtagh@precisionaq.com | sr@roberts-communications.com | ||
| 678-384-7220 | 212-698-8696 | 202-779-0929 |
/AI%20(artificial%20intelligence)/AI%20engineer%20working%20on%20laptop%20by%20ART%20STOCK%20CREATIVE%20via%20Shutterstock.jpg)
/Semiconductor%20by%20Gorodenkoff%20via%20Shutterstock.jpg)